ultrasensitive detection of disease and biomarkers
Intellectual Property & Licensing
Novilux has put in place formidable barriers to entry for competitors including:
-
High number of issued patents with broad claims ​
-
Significant internally developed trade secret IP and know-how in consumables, fluidics, assays, optics, signal and image processing, and alignment / fabrication techniques
-
New patent applications with allowed claims covering novel concepts incorporated into the Point-of-Care product
Novilux patents and out-licensing program ensure a strong and growing future for its technology.
By the Numbers
55
Issued Patents
14
Individual Jurisdictions
19
Applications in process
3
Out-Licenses
Out-Licensing Agreements
Novilux has strategically out-licensed technology with royalty-based, straight cash, exclusive and non-exclusive agreements.
-
MilliporeSigma / Merck KGaA – Research tools. Multitudes of researchers around the world using SMC™ to discover new, clinically effective biomarkers.
-
Grifols – Blood screening. Next generation platforms in development using Novilux SMC™ technology.
-
Undisclosed – completed in late 2022, non-exclusive rights to use SMC™ technology in a limited field.
o Key agreements in place expanding the use of Novilux SMC™ technology.